The potential economic value of a 'universal' (multi-year) influenza vaccine

Influenza and other Respiratory Viruses

Volumn 6, Issue 3, 2012, Pages 167-175

  Lee, Bruce Y ^a,b   Tai, Julie H Y ^a,b   McGlone, Sarah M ^a,b   Bailey, Rachel R ^a,b   Wateska, Angela R ^a,b   Zimmer, Shanta M ^a   Zimmerman, Richard K ^a   Wagner, Michael M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness; Economics; Influenza vaccine; Pediatrics; Universal vaccine

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; INFANT; INFLUENZA VACCINATION; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MONTE CARLO METHOD; VACCINATION; YOUNG ADULT;

EID: 84859771153     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2011.00288.x     Document Type: Article

References (48)

1. Fiore AE, Shay DK, Broder K et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1-52.
2. Centers for Disease Control and Prevention. Influenza vaccination coverage among children and adults - United States, 2008-09 influenza season. MMWR Morb Mortal Wkly Rep 2009; 58:1091-1095.
3. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009; 8:499-508.
4. Smith DJ, Lapedes AS, de Jong JC et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004; 305:371-376.
5. Lee BY, Burke DS. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 2010; 28:2806-2809.
6. Centers for Disease Control and Prevention. Seasonal Influenza (Flu): Key Facts About Seasonal Flu Vaccine. Atlanta, GA: Centers for Disease Control and Prevention, 2011.
7. Rivetti D, Jefferson T, Thomas R et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006; 3:CD004876.
8. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998; 36:778-792.
9. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2000; 19:92-109.
10. United States Census Bureau. Annual Estimates of the Resident Population by Sex and Five-Year Age Groups for the United States: April 1, 2000 to July 1, 2009.
11. PDR Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thompson Healthcare, Inc., 2010.
12. Xu J, Kochanek DK, Tejada-Vera B. Deaths: preliminary data for 2007. Natl Vital Stat Rep 2009; 58.
13. Shepard DS. Cost-effectiveness in health and medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). New York: Oxford University Press, 1996. J Ment Health Policy Econ 1999; 2:91-92.
14. Human Mortality Database. University of California (Berkeley) and Max Plank Institute for Demographic Research (Germany), 2008 Available from:.
15. Ling LM, Chow AL, Lye DC et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50:963-969.
16. Carrat F, Vergu E, Ferguson NM et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008; 167:775-785.
17. Lee BY, Tai JH, Bailey RR, Smith KJ. The timing of influenza vaccination for older adults (65years and older). Vaccine 2009; 27:7110-7115.
18. Lee BY, Tai JH, Bailey RR, Smith KJ, Nowalk AJ. Economics of influenza vaccine administration timing for children. Am J Manag Care 2010; 16:e75-e85.
19. Lee BY, Brown ST, Cooley PC et al. A computer simulation of employee vaccination to mitigate an influenza epidemic. Am J Prev Med 2010; 38:247-257.
20. Lee BY, Brown ST, Korch GW et al. A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine 2010; 28:4875-4879.
21. Du L, Zhou Y, Jiang S. Research and development of universal influenza vaccines. Microbes Infect 2010; 12:280-286.
22. Fiers W, De Filette M, El Bakkouri K et al. M2e-based universal influenza A vaccine. Vaccine 2009; 27:6280-6283.
23. Ekiert DC, Bhabha G, Elsliger MA et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-251.
24. Chen GL, Subbarao K. Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine. Nat Med 2009; 15:1251-1252.
25. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010; 16:1389-1391.
26. Donis RO, Cox NJ. Prospecting the influenza hemagglutinin to develop universal vaccines. Clin Infect Dis 2011; 52:1010-1012.
27. Wang TT, Tan GS, Hai R et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 2010; 107:18979-18984.
28. World Health Organization. Initiative for Vaccine Research (IVR): Tables on the Clinical Trials of Pandemic Influenza Prototype Vaccines. 2011.
29. US National Institutes of Health. Clinical Trials Gov. A double-dose safety study of an influenza vaccine (Multimeric-001). 2009.
30. Ben-Yedidia T. Multimeric-001: BiondVax's universal flu vaccine. Interview by Duc Le. Expert Rev Vaccines 2010; 9:241-242.
31. US National Institutes of Health. Clinical Trials Gov. A double-dose safety study of an influenza vaccine (Multimeric-001) injected to elderly volunteers. 2009.
32. Wrammert J, Koutsonanos D, Li GM et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208:181-193.
33. Berthoud TK, Hamill M, Lillie PJ et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011; 52:1-7.
34. Wilkinson E. Universal flu vaccine tests start. BBC News, 2008.
35. Bureau of Labor Statistics. May 2008 National Occupation Employment and Wage Estimates, United States. 2008.
36. American Medical Association. Socioeconomics of Medical Practice. Gonzales M (ed.) Chicago, IL: American Medical Association, 1997; p. 69, 89, 107.
37. United States Department of Health and Human Services. Centers for Medicare & Services. 2009.
38. United States Department of Health and Human Services. HCUP facts and figures. Statistics on hospital-based care in the United States in 2007, 2008.
39. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999; 130:789-799.
40. Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics 2008; 26:911-924.
41. Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med 2002; 113:300-307.
42. Hawkes M, Schuh S, Ipp M et al. Natural history of pandemic H1N1 2009 influenza infection in healthy pediatric outpatients. Acad Pediatr 2011; 11:66-74.
43. Centers for Disease Control and Prevention. Possible Side-effects from Vaccines. Atlanta, GA: Centers for Disease Control and Prevention. Available at: (Accessed 11 August 2009).
44. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis 1978; 31:697-704.
45. Allsup S, Haycox A, Regan M, Gosney M. Is influenza vaccination cost effective for healthy people between ages 65 and 74years? A randomised controlled trial. Vaccine 2004; 23:639-645.
46. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38:583-637.
47. Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-5096.
48. Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-696.